Eur J Med Res. 2025 Jul 14;30(1):618. doi: 10.1186/s40001-025-02892-x.
ABSTRACT
BACKGROUND: Autoimmune diseases (AID) have been showed to be susceptibility to malignancy. This study aimed to analyzed the profile of serum tumor markers in four common autoimmune disease.
METHODS: Patients with dermatomyositis (DM, n = 132), Systemic sclerosis (SSc, n = 77), Systemic lupus erythematosus (SLE, n = 191), Rheumatoid arthritis (RA, n = 160) and ovarian cancer (n = 250) were included in this study. Twelve tumor markers (CA724, AFP, FRT, NSE, CA19-9, CA125, CYFRA21-1, CA153, β-HCG and HE4) levels and abnormal rate in these patients were retrospective statistics. The tumor markers profiles were compared among the different AID.
RESULTS: Compared with ovarian cancer (OV) patients, there were no significant differences for the levels and abnormal rates of CYFRA21-1/HE4/CA50/FRT in AID patients. The levels and abnormal rates of CA724/FRT/CA125/NSE were higher in OV patients than that in AID patients. 75% AID patients have at least one elevated tumor marker. 69.46% AID patients have 2-5 elevated tumor markers. All the 12 tumor markers were negative in 16.67, 19.74, 27.23 and 32.70% of DM, SSc, SLE and RA patients. Except CA50, the levels of the other eleven tumor markers were significantly different between DM/SSc/SLE/RA. Except AFP/β-HCG/SCC, the abnormal rate of the other tumor markers were significantly different between these AID.
CONCLUSIONS: The increased levels of tumor makers were common in four major AID, and the profile of tumor makers were significantly different among these AID.
PMID:40660406 | DOI:10.1186/s40001-025-02892-x
